Generative AI tools, particularly large language models (LLMs) have become indispensable for creating marketing content at lightning speed. Healthcare providers now routinely use them to write website content, service descriptions, blog posts, patient education materials, and outreach emails. These tools produce polished, confident prose almost instantly. The problem: they do not produce careful, accurate, or legally compliant prose. In healthcare marketing, that distinction is not a minor inconvenience – it is a direct path to Federal Trade Commission (FTC) enforcement.

There Is No “The AI Did It” Defense

When AI-generated content is published on your website, social channels, blog, or promotional materials, every claim becomes your claim. The FTC treats those statements exactly the same as if your marketing director wrote them by hand.

Here are common examples of routine LLM hallucinations:

• Precise but entirely fictitious statistics (“97% of patients achieve complete pain relief”);

• Exaggerated outcomes and timelines;

• Incorrect FDA regulatory status (“FDA-approved” for devices that are merely cleared);

• Fake clinical citations and fabricated study results;

• Fabricated or heavily embellished patient testimonials.

Each of these is potentially deceptive advertising under Section 5 of the FTC Act. Healthcare claims carry an especially high burden: they must be substantiated with competent and reliable scientific evidence before they are disseminated; not after the FTC comes knocking.

Phrases AI Loves That the FTC Hates

Large language models are trained on the internet, so they naturally reproduce the vague, results-oriented language that dominates healthcare marketing:

• “Fast, lasting results”

• “Proven effective treatment”

• “Clinically superior”

• “Safe, non-surgical alternative”

These phrases sound compelling, but without rigorous scientific backing they are considered implied efficacy claims. The FTC has repeatedly stated that health-related promises, explicit or implied, require high-quality evidence. Shortcuts are not permitted.

Testimonials and Success Stories: Even Higher Risk

If an LLM generates or “enhances” patient stories, the FTC views them as fabricated endorsements. Even genuine testimonials become problematic if they present atypical results without clear, conspicuous disclosures about what consumers can generally expect.

The Commission has brought numerous cases against providers for exactly this issue. AI simply accelerates the creation of non-compliant testimonials at scale.

AI Chatbots Are Advertisers – Not Casual Conversationalists

More healthcare websites now feature AI chatbots to answer prospective patient questions. When a chatbot responds to inquiries such as:

• “How effective is this treatment for chronic pain?”

• “How long is the typical recovery?”

• “Is this FDA-approved?”

… those answers are marketing representations, not informal conversation. Overstatements, implied guarantees, or unsubstantiated claims made by the chatbot are attributable directly to the practice. The enforcement risk is significant and growing.

The Overlooked HIPAA Intersection

Many marketing teams unknowingly violate HIPAA when they paste actual patient reviews, case details, or questions into public LLM tools (ChatGPT, Claude, Gemini, etc.) to generate responses or improved copy. Doing so can disclose protected health information to a third party without a Business Associate Agreement, which is a separate regulatory violation that compounds the advertising problems.

How to Use AI Without Creating Liability

Healthcare providers can and should leverage AI, but only with strong guardrails:

• Require mandatory human review by someone specifically trained in FTC and FDA advertising requirements.

• Prohibit AI from generating statistics, success rates, FDA status, or scientific claims unless independently verified.

• Ban the creation of fictional testimonials or patient success stories.

• Implement clear disclaimers for AI chat tools and live oversight where feasible.

• Include contractual provisions with marketing agencies and AI vendors that allocate liability for non-compliant content.

Bottom Line

In healthcare, credibility is the brand. Patients make treatment decisions based on the information you publish. When AI exaggerates outcomes, invents data, or borrows unearned medical authority, the practice – not the AI company – bears the full regulatory and reputational risk.

The FTC is not slowing down its enforcement in this area, and “the algorithm wrote it” is not a defense. Forward-thinking providers treat AI as a powerful assistant rather than an autonomous voice. With proper oversight and compliance processes, you can achieve marketing efficiency without inviting avoidable liability.

Our firm helps healthcare providers implement AI-compliant marketing workflows, review existing content for FTC risk, and defend enforcement actions when necessary. If you are using generative AI for any patient-facing materials, now is the time to verify your content meets regulatory standards. For tailored counsel on integrating AI responsibly, contact our healthcare attorneys at (212) 668-0200 or info@mdrxlaw.com.